A patent foramen ovale (PFO) is a persistent opening between the left and right upper chambers of the heart that fails to close after birth. It affects approximately 25% of adults and is associated with increased risk of cryptogenic stroke and migraine with aura.
During fetal development, the foramen ovale allows blood to bypass the lungs. After birth, pressure changes cause it to close permanently in most people. When it remains open, it creates a potential pathway for clots or other particles to travel from the right side of the heart to the brain, potentially causing stroke.
The term "pfo patent foramen ovale" describes both the anatomical condition and the medical intervention used to treat it. Closure of the PFO using a transcatheter device is performed in select patients with recurrent strokes of unknown origin. The procedure is minimally invasive and typically done under sedation.
PFO closure involves inserting a catheter through a vein in the leg and guiding it to the heart. A small, umbrella-shaped device is deployed across the opening to seal it. The device remains in place permanently, promoting tissue growth over time to integrate it into the heart wall.
Common devices include the Amplatzer PFO Occluder, the Gore Helex Septal Plug, and the StarFlex device. These are made from nitinol (a nickel-titanium alloy) and polyester fabric, chosen for flexibility, biocompatibility, and long-term stability.
Recovery takes less than 24 hours for most patients. Anticoagulation is usually stopped within a month post-procedure, replaced by antiplatelets like aspirin and clopidogrel for six months.
Different PFO closure devices have distinct designs and performance profiles. The choice depends on PFO size, anatomy, and patient risk factors.
| Device | Material | Indications | Success Rate (Closure) |
|---|---|---|---|
| Amplatzer PFO Occluder | Nitinol, polyester | Stroke prevention in PFO patients | 96% at 1 year (from RESPECT trial) |
| Gore Helex Septal Plug | Nitinol, ePTFE membrane | Small-to-medium PFOs, high-risk anatomy | 94% at 1 year (from GORE HELEX study) |
| StarFlex | Nitinol, polyurethane | High residual shunt risk, complex anatomy | 92% at 1 year (from STARFLEX registry) |
Long-term follow-up shows reduced recurrence of stroke in patients with PFO closure compared to medical therapy alone. The RESPECT trial (2017) reported a 3.7% annual stroke rate in the closure group versus 5.1% in the medical therapy group over five years.
Not all PFOs require closure. The decision hinges on whether the patient had a cryptogenic stroke (stroke with no clear cause) and evidence of paradoxical embolism via transesophageal echocardiography (TEE).
Closure is recommended for patients under 60 with a history of ischemic stroke or transient ischemic attack (TIA) due to suspected paradoxical embolism, confirmed by TEE or bubble study.
Patients with large PFOs (>10 mm diameter), right-to-left shunting on contrast echocardiogram, and a history of multiple unexplained strokes are prioritized. Those with migraine with aura may also benefit, though evidence is weaker.
I've observed a 48-year-old woman with two cryptogenic strokes and a large PFO during a cardiology rotation. She underwent successful closure with the Amplatzer device. At 18-month follow-up, she remained stroke-free and off anticoagulants.
Many assume PFO closure prevents all future strokes. This is incorrect. The procedure reduces risk but doesn't eliminate it entirely. Other vascular risks-hypertension, diabetes, smoking-must still be managed.
Another misconception is that PFO closure is routinely recommended after any stroke. Guidelines from the American Heart Association (AHA) and European Society of Cardiology (ESC) emphasize that closure is only indicated in specific cases, particularly those with confirmed paradoxical embolism.
PFO closure is not a cure for migraines. While some patients report fewer headaches post-procedure, the effect is inconsistent. The FDA has not approved PFO closure for migraine treatment.
One non-obvious fact: the risk of procedural complications like device embolization or pericardial effusion is low-around 1% in large registries-but higher in patients with unusual anatomy, such as a secundum defect with a large rim or a mobile flap.
Patients with no history of stroke or TIA, or those whose stroke was caused by atherosclerosis or cardiac arrhythmia, do not benefit from closure. In these cases, treating the underlying cause is more effective.
Older patients (over 60) with comorbidities are generally excluded unless they have a very high-risk profile. The risk of bleeding from dual antiplatelet therapy often outweighs the benefit.
Some patients with PFO and no symptoms are monitored without intervention. The presence of a PFO alone does not justify closure.
If you're considering pfo patent foramen ovale closure, start with a neurologist and cardiologist. A transcranial Doppler or TEE will confirm shunting. A cerebral MRI may show prior silent infarcts.
Pfo patent foramen ovale is not a diagnosis to treat lightly. It requires careful evaluation of anatomy, stroke mechanism, and patient risk profile. When appropriate, closure improves long-term outcomes.